anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Research on media's effects on body perception has mainly focused on the role of vision of extreme body types. However, haptics is a major part of the way children experience bodies. Playing with unrealistically thin dolls has been linked to the emergence of body image concerns, but the perceptual mechanisms remain unknown. We explore the effects of haptic experience of extreme body types on body perception, using adaptation aftereffects. Blindfolded participants judged whether the doll-like stimuli explored haptically were thinner or fatter than the average body before and after adaptation to an underweight or overweight doll. In a second experiment, participants underwent a traditional visual adaptation paradigm to extreme bodies, using stimuli matched to those in Experiment 1. For both modalities, after adaptation to an underweight body test bodies were judged as fatter. Adaptation to an overweight body produced opposite results. For the first time, we show adiposity aftereffects in haptic modality, analogous to those established in vision, using matched stimuli across visual and haptic paradigms.
The plan is to study the safety and efficacy of CG0070 in high-grade NMIBC (Non-muscle Invasive Bladder Cancer) patients who failed BCG therapy. Most patients with NMIBCis (Cis, Cis with Ta and/or T1, high grade Ta or T1 with frequent or uncontrolled recurrences) who have failed BCG (Bacillus Calmette-Guerin) intravesical therapy (standard of care) usually have no other choice but to proceed to cystectomy. Cystectomy is a surgery associated with major morbidity, mortality and quality of life issues. Morbidity and long term tedious medical care will be for the rest of the patient's life span. Most patients at this stage do not show signs of disease progression into the muscle layer or of metastasis, making surgery a very difficult decision. CG0070, if successful in this trial, will serve to provide a therapeutic alternative for this patient population in need.
PURPOSE: Robot-assisted radical prostatectomy (RARP) is a common surgical procedure for the treatment of prostate cancer. Although beneficial, it can lead to intraoperative hypoxia due to high-pressure pneumoperitoneum and Trendelenburg position. This study explored the use of oxygen reserve index (ORi) to monitor and predict hypoxia during RARP.
METHODS: A retrospective analysis was conducted on 329 patients who underwent RARP at the Seoul National University Bundang Hospital between July 2021 and March 2023. Various pre- and intraoperative variables were collected, including ORi values. The relationship between ORi values and hypoxia occurrence was assessed using receiver operating characteristic curves and logistic regression analysis.
RESULTS: Intraoperative hypoxia occurred in 18.8% of the patients. The receiver operating characteristic curve showed a satisfactory area under the curve of 0.762, with the ideal ORi cut-off value for predicting hypoxia set at 0.16. Sensitivity and specificity were 64.5% and 75.7%, respectively. An ORi value of < 0.16 and a higher body mass index were identified as independent risk factors of hypoxia during RARP.
CONCLUSIONS: ORi monitoring provides a non-invasive approach to predict intraoperative hypoxia during RARP, enabling early management. Additionally, the significant relationship between a higher body mass index and hypoxia underscores the importance of individualized patient assessment.
SUMMARYThe genus Streptococcus consists of a taxonomically diverse group of Gram-positive bacteria that have earned significant scientific interest due to their physiological and pathogenic characteristics. Within the genus Streptococcus, viridans group streptococci (VGS) play a significant role in the oral ecosystem, constituting approximately 80% of the oral biofilm. Their primary role as pioneering colonizers in the oral cavity with multifaceted interactions like adherence, metabolic signaling, and quorum sensing contributes significantly to the complex dynamics of the oral biofilm, thus shaping oral health and disease outcomes. Perturbations in oral streptococci composition drive oral dysbiosis and therefore impact host-pathogen interactions, resulting in oral inflammation and representing VGS as an opportunistic pathogen. The association of oral streptococci in tumors across distant organs, spanning the esophagus, stomach, pancreas, and colon, illuminates a potential association between oral streptococci, inflammation, and tumorigenesis. This finding emphasizes the need for further investigations into the role of oral streptococci in mucosal homeostasis and their involvement in carcinogenesis. Hence, here, we review the significance of oral streptococci in biofilm dynamics and how the perturbation may impact mucosal immunopathogenesis in the context of cancer, with a vision of exploiting oral streptococci for cancer intervention and for the development of non-invasive cancer diagnosis.
Systemic hyperinflammation is a hallmark of more severe stages of COVID-19 leading to acute respiratory distress syndrome, mechanical ventilation and ultimately death. In this stage, COVID-19 is associated with a decrease in suppressor and regulatory T cell counts and an extensive release of proinflammatory cytokines and biomarkers called a cytokine storm, which is thought to be the major driver of severe pneumonia caused by SARS-CoV-2. C1 esterase inhibitor (C1INH) is a member of the serpin superfamily of serine-protease inhibitors and is a strong inhibitor of the complement System (CS) and the kinin-kallikrein (KK) System. Conestat alfa is a recombinant human C1INH, that shares an identical protein structure with plasma-derived C1INH. The rationale of the current trial is based upon the following assumptions: In the context of COVID-19, conestat alfa treatment may 1) dampen uncontrolled complement activation and collateral lung damage and 2) reduce capillary leakage and subsequent pulmonary edema by direct inhibition of KK system. The aim of this study is to analyze administration of conestat alfa for 72 hours in addition to standard of care in patients hospitalized with non-critical SARS-CoV-2 pneumonia (WHO Ordinal Scale Score 3 or 4) and its association with clinical severity on day 7 after inclusion and the risk of disease progression to Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS).
OBJECTIVES: Frequent gout attacks in the initial introduction of urate-lowering therapy (ULT) are significant causes of poor drug adherence and ULT discontinuation. Initial low-dose urate-lowering drugs may be effective in reducing gout flares, however robust evidence is sparse. The aim of this study was therefore to assess the association of initial dose urate-lowering drugs with gout flares in adult males with gout during the initial introduction of ULT.
METHODS: This cohort study obtained data on consecutive gout patients from a single-centre gout cohort study from August 2017 to October 2020. A standard questionnaire was applied to collect demographic and clinical information, and biochemical parameters were tested on the same day. The primary endpoint was to estimate the association of initial dose febuxostat with gout flares, using Cox hazard models with inverse probability of treatment weighting (IPTW).
RESULTS: A total of 582 gout patients were included in this study. During the 6-week follow-up, 71 (12.2%) patients suffered gout flares. In the main analysis using Cox hazard models with IPTW, compared with colchicine prophylaxis, initial low-dose febuxostat alone had no statistical significance with the increased risk of gout flares [hazard ratio (HR) 1.26; 95% CI 0.58, 2.72], while initial high-dose febuxostat was associated with an increased risk of gout flares (HR 3.08; 95% CI 1.34, 7.07).
CONCLUSIONS: This observational study demonstrated that initial low-dose febuxostat was equally effective in preventing gout flares as colchicine prophylaxis, while initial high-dose febuxostat alone was associated with an increased risk of gout flares.
A chimeric antigen receptors (CARs) specific to B-cell maturation antigen (BCMA), a recombinant expression vector and a method for the development of the genetically modified immune effector cells especially natural killer-92 cells (NK-92 cells) that target Multiple Myeloma (MM) and other hematological malignancies. The invention encompasses a single chain variable region (scFv) from BCMA specific antibody fused via transmembrane domain to intracellular signaling domain and two co-stimulatory molecules. Expression of CARs across the plasma membrane of immune effector cells such as natural killer cells (NK cells), NK-92 cells, T lymphocytes (T cells) and natural killer T cells (NKT cells) with exposed scFv interacting with the BCMA tumor target. The interaction initiates cascade of events through the intracellular stimulatory and signaling domains leading to the activation of immune effector cells followed by lysis of the tumor. The invention also includes methods of administering a genetically modified immune effector cells expressing a CAR that comprises a BCMA binding domain. FIG.  4  is the representative figure.
PURPOSE: To obtain the subject new compound by culturing a fungus belonging to the genus Penicillium, capable of producing a physiologically active substance NK374,186 analog, having inhibitory action on proliferation of cell and controlling action on blastgenesis of lymphocyte, useful as an antitumor agent, immunomodulating agent, etc. CONSTITUTION: A new NK374186 analog (salt) of the formula [one of (m) and (n) is 1 and the other is 0; R is a 13C alkyl; P1 is hydroxyl group or phosphate group; A1 is CH-CH(CH3 )-X1 (X1 is OH, an inorganic acid group or a 1-7C organic acid group) or C=CH-CH3 ; A2 is CHCH2 X2 (X2 is shown as X1 ) or C=CH2 ]. This compound has inhibitory action on proliferation of cell and controlling action on blastgenesis of lymphocyte and is useful as an antitumor agent, immunomodulating agent, etc. The compound is obtained by culturing a fungus [e.g. Penicillium NK374186 strain (FERM P-12,285), etc.] belonging to the genus Penicillium, capable of producing the physiologically active substance NK374,186 analog in a medium and collecting the product from the culture product.
Genome replication is frequently impeded by highly stable DNA secondary structures, including G-quadruplex (G4) DNA, that can hinder the progression of the replication fork. Human WRNIP1 (Werner helicase Interacting Protein 1) associates with various components of the replication machinery and plays a crucial role in genome maintenance processes. However, its detailed function is still not fully understood. Here we show that human WRNIP1 interacts with G4 structures and provide evidence for its contribution to G4 processing. The absence of WRNIP1 results in elevated levels of G4 structures, DNA damage and chromosome aberrations following treatment with PhenDC3, a G4-stabilizing ligand. Additionally, we establish a functional and physical relationship between WRNIP1 and the PIF1 helicase in G4 processing. In summary, our results suggest that WRNIP1 aids genome replication and maintenance by regulating G4 processing and this activity relies on Pif1 DNA helicase.
Pharmaceutical pulmonary compositions, methods of delivery to the lungs of a human and methods of treatment thereof. Pharmaceutical formulations including 1α,25-dihydroxyvitamin D3, an alcohol such as ethanol, and a polyol such as propylene glycol. Another pharmaceutical pulmonary formulation includes 1α,25-dihydroxyvitamin D3 and dry bulking powder, which is used in a dry powder inhaler. Another pharmaceutical formulation includes 1α,25-dihydroxyvitamin D3 and an aerosol propellant, which is used in a metered dose inhaler. The pharmaceutical pulmonary formulations may include a second active pharmaceutical ingredient such as calcitonin or a N-terminal peptide fragment of parathyroid hormone consisting of the first (34) to (38) amino acids of SEQ ID No. 1. Pulmonary delivery of the formulations efficaciously increase serum calcium levels in mammals, manage hypocalcemia, treat calcium metabolic disorder and reduce elevated parathyroid hormone levels.
BACKGROUND: Hemodialysis is one of the treatment methods for chronic kidney disease, which is a common disease around the world. The problems that occur during the hemodialysis process may cause discomfort in patients. Therefore, it is important to regularly evaluate the concept of comfort in hemodialysis patients.
AIM: To determine the comfort level of patients undergoing hemodialysis and the associated factors.
METHODS: This study was a descriptive cross-sectional study conducted among 95 patients who had been undergoing hemodialysis for at least 6 months. Data were collected using the sociodemographic characteristics form and the Hemodialysis Comfort Scale (HDCS).
RESULTS: The mean age of the participants was 58.37 ± 16.62 years. The median duration of hemodialysis was 5 (1-25) years. A total of 51% of the patients were male, 54.7% were married, 34.7% had completed primary school, and 85.3% had a comorbid chronic disease. The mean hemodialysis comfort score was 23.85 ± 6.93. The mean score was significantly higher in male patients (P = 0.041) and those without comorbid chronic disease (P = 0.013). There was a significant negative correlation between the age of hemodialysis patients and the mean hemodialysis comfort score (r = -0.260, P = 0.011).
CONCLUSION: The comfort level was significantly better in hemodialysis patients who were male, those without comorbid disease, and those who were younger. There is a need to periodically assess the comfort level of hemodialysis patients and intervene when necessary in order to improve their quality of life.
Beta-adrenergic receptor antagonists (beta-blockers) and STRIVERDI RESPIMAT may interfere with the effect of each other when administered concurrently. Beta-blockers not only block the therapeutic effects of beta-agonists, but may produce severe bronchospasm in COPD patients. Therefore, patients with COPD should not normally be treated with beta-blockers. However, under certain circumstances, e.g. as prophylaxis after myocardial infarction, there may be no acceptable alternatives to the use of beta-blockers in patients with COPD. In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution.
Regular menstruation is a key indicator of general health and irregular menstrual parameters have been associated with elevated risk of adverse health outcomes. While psychological stress is believed to contribute to abnormal menstruation, little is known of the effects of discrete psychological stressors, including the COVID-19 pandemic, on menstrual function. A systematic database search was performed and studies investigating the relation between psychological stress and menstrual cycle irregularity in otherwise healthy adults were included. Two independent investigators completed abstract and full-text screening, data extraction, and risk of bias assessment. In the 41 included studies, a variety of stressors were assessed, namely COVID-19 pandemic stress, academic stress, and occupational stress. Our review found most studies report an association between psychological stress and menstrual dysfunction, with the most common disruptions being irregular menstruation and abnormal menstrual flow. Our findings also underlined notable discrepancies in the operational definitions used in the study of menstrual disorders. These observations emphasize the importance of psychological stress as a modifiable risk factor associated with irregular menstruation.
Involves four 60-minute occupational therapy visits as well as a daily home program across a 8-week period. Clinic visits focus primarily on home program coaching, and progression of the exercise regimen. Home programs involve daily exercises which follow the intensity and duration recommended for older adults. The intervention focuses on enhancing mobility and strength of the thumb for use during daily activities.
The intervention will utilize the Cognitive Behavioral Therapy (CBT), an evidence-based psychotherapeutic approach to addressing mental health issues ranging from anxiety, depression, and other mental illnesses. CBT is based on a cognitive model, the way that individuals perceive a situation is more closely connected to their reaction than the situation itself. The purpose of CBT is to help people focus on how to solve their current problems. The therapist helps the patient learn how to identify distorted or unhelpful thinking patterns, recognize and change inaccurate beliefs, relate to others in more positive ways, and change behaviors accordingly. Participants in the intervention arm will receive 12 weekly, one-hour, group CBT sessions, and three, one-hour, one-on-one therapy sessions throughout the 12-week Father For a LIfetime (FFL) program. We will implement an individual and group CBT mental health intervention that will align with the topics addressed in the FFL weekly curriculum. For instance, the group CBT intervention will examine methods to build resiliency, develop skills to remain calm in stressful situations, learn coping skills when separated from their child/children, and learn how to cope with strained relationships. The FFL curriculum is adapted from the Wise Guys: Male Responsibility Curriculum, an evidence-informed curriculum designed to engage males in the prevention of pregnancies. The curriculum topics are broken into three categories: 1) personal responsibility, 2) responsibility to your child and 3) responsibility to your family and community. Figure 1 below displays the topic description covered each week within each category. The intention of our proposed therapeutic mental health intervention is to improve mental health status utilizing CBT in a group setting and initiating treatment of specific mental illnesses in the one-on-one therapy sessions to meet the unique needs of the father that may not be addressed in a group setting. Participants will receive the intervention immediately after the FFL programming concludes.

The intervention will be delivered by a gender and culturally-matched Licensed Mental Health Professional (LIMHP) who will be trained to deliver the curriculum by the co-investigator and Senior Director of Behavioral Health Services at Charles Drew Health Center. In addition, the men will receive three one-on-one therapy sessions with a Charles Drew LIMHP that will be completed by the end of the FFL program. Participants in the comparison arm will receive the standard, 12-week program curriculum. Our proposed study falls within the T3 translational spectrum, which includes testing an intervention within a community setting by observing and gathering information on implementation to determine feasibility or effectiveness.
The invention relates to a composition for treating cancer. The composition is characterized by comprising the following components in percentage by weight: 10-30% of a ganoderma lucidum seed entity extract, 10-30% of ganoderma spores and 40-80% of Zhiling, wherein the best ratio is 1:1:1.5. The dosage forms of the composition comprise hard capsules, soft capsules, tablets (including common tablets, disintegrating tablets, lozenges and chewable tablets), granules and pills, namely the dosage forms for oral administration. The preparation method of the composition is characterized by comprising the following steps of: extracting a ganoderma lucidum seed entity with 60% ethanol at first, then extracting with water, and combining to obtain the ganoderma lucidum seed entity extract; and physically breaking the walls of the ganoderma spores at low temperature and normal pressure, wherein the wall breaking ratio reaches more than 95%, and the particle size is 0.4-0.5 micron. The composition is favorable for absorption by human bodies, and convenient to use. A national clinical verification base verifies that the composition has an auxiliary treatment effect on chemoradiotherapy of tumors and hepatopathy.
Infectious diseases, such as umbilical cord infection, pneumonia, and sepsis, are responsible for about a quarter of neonatal deaths. Contaminated hands likely play a role in transmitting pathogens to a neonate, therefore handwashing with soap has the potential to interrupt transmission and improve neonatal health. The primary objective of this study is to develop and evaluate a scalable, cost-effective handwashing promotion program to improve handwashing behavior among mothers and caregivers of neonates. The investigators will first conduct a qualitative study to assess the feasibility and acceptability of a set of interventions. The investigators propose to evaluate the impact of the intervention components, designed as three progressively intense interventions, using a randomized controlled trial with elements of a stepped wedge design. The study will be conducted in Meru County, Kenya, enrolling a total of 800 pregnant women who seek non-emergency antenatal care at a government health facility during a 1 year period. Clinic based health care workers and community health volunteers will disseminate the intervention using an interactive storytelling approach. The focus of the interactions between the health care workers and volunteers and the participant will be on addressing barriers to handwashing through interactive question and answer sessions, rather than a didactic, educational session. The investigators will assess the impact of interventions on observed maternal and caregiver handwashing behavior and estimate the cost effectiveness for each intervention.
A method for determining whether a factor is a modulator of the transmission of immunity from a female mammal to newborn mammals by consumption of milk from the female. A female mammal, such as a BALB/C female mouse, is exposed to the factor, and then immunized to one or more antigens. The female is then made to lactate, and newborn mammals are allowed to consume milk obtained from the lactating female. The newborns are then inoculated with the one or more antigens. The level of immunity in the newborns to the one or more antigens is then compared to that in control newborns that received milk from a female that was immunized against the one or more antigens but not exposed to the factor. A difference between the level of immunity to the one or more antigens in the experimental newborns and the control newborns is indicative that the factor is a modulator of the transmission of immunity to the one or more antigens from a female mammal to newborn mammals by consumption of milk from the female.
Participants in the Training arm will undergo 15 hours of computerized auditory training across 10 laboratory visits. Medial olivocochlear reflex function and speech perception abilities will be measured before, during, and after the training visits to examine the changes in the measurements across time.